• Explore /
  • Poster
  • / A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.

A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.

Abstract Poster

Authors

null

Tae-Yong Kim

Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea;

Tae-Yong Kim , Jeesun Yoon , Dae-Won Lee , Seock-Ah Im , Ah-Rong Nam , Ju-Hee Bang , Kyoung-Seok Oh , Jae-Min Kim , Yoojin Jeong , Sea Young Choo , Hyo Jung Kim , Su In Lee , Do-Youn Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03579784

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 404)

DOI

10.1200/JCO.2023.41.4_suppl.404

Abstract #

404

Poster Bd #

H7

Abstract Disclosures

Similar Posters

First Author: Minsuk Kwon

First Author: Tae Yong Kim

Poster

2023 ASCO Annual Meeting

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

First Author: Lili Mao

First Author: Koichi Azuma